| The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative P Sati, J Oh, RT Constable, N Evangelou, CRG Guttmann, RG Henry, ... Nature Reviews Neurology 12 (12), 714-722, 2016 | 403 | 2016 |
| Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function D Ontaneda, AJ Thompson, RJ Fox, JA Cohen The Lancet 389 (10076), 1357-1366, 2017 | 372 | 2017 |
| Phase 2 trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ... New England Journal of Medicine 379 (9), 846-855, 2018 | 294 | 2018 |
| Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives D Ontaneda, RJ Fox, J Chataway The Lancet Neurology 14 (2), 208-223, 2015 | 268 | 2015 |
| Cell-based therapeutic strategies for multiple sclerosis NJ Scolding, M Pasquini, SC Reingold, JA Cohen Brain 140 (11), 2776-2796, 2017 | 198 | 2017 |
| Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis D Ontaneda, E Tallantyre, T Kalincik, SM Planchon, N Evangelou The Lancet Neurology 18 (10), 973-980, 2019 | 177 | 2019 |
| Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study BD Trapp, M Vignos, J Dudman, A Chang, E Fisher, SM Staugaitis, ... The Lancet Neurology 17 (10), 870-884, 2018 | 166 | 2018 |
| Measuring myelin repair and axonal loss with diffusion tensor imaging RJ Fox, T Cronin, J Lin, X Wang, K Sakaie, D Ontaneda, SY Mahmoud, ... American Journal of Neuroradiology 32 (1), 85-91, 2011 | 150 | 2011 |
| Multiple sclerosis: new insights in pathogenesis and novel therapeutics D Ontaneda, M Hyland, JA Cohen Annual review of medicine 63 (1), 389-404, 2012 | 111 | 2012 |
| Progressive multiple sclerosis D Ontaneda, RJ Fox Current opinion in neurology 28 (3), 237-243, 2015 | 110 | 2015 |
| T1‐/T2‐weighted ratio differs in demyelinated cortex in multiple sclerosis K Nakamura, JT Chen, D Ontaneda, RJ Fox, BD Trapp Annals of neurology 82 (4), 635-639, 2017 | 107 | 2017 |
| Multiple sclerosis management during the COVID-19 pandemic BP Moss, KR Mahajan, RA Bermel, K Hellisz, LH Hua, T Hudec, S Husak, ... Multiple Sclerosis Journal 26 (10), 1163-1171, 2020 | 88 | 2020 |
| Diagnosis and management of progressive multiple sclerosis G Macaron, D Ontaneda Biomedicines 7 (3), 56, 2019 | 86 | 2019 |
| Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) task force on clinical disability measures D Ontaneda, N LaRocca, T Coetzee, RA Rudick Multiple Sclerosis Journal 18 (8), 1074-1080, 2012 | 83 | 2012 |
| Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm AJ Solomon, R Watts, D Ontaneda, M Absinta, P Sati, DS Reich Multiple Sclerosis Journal 24 (6), 750-757, 2018 | 81 | 2018 |
| Impacts of climate change and air pollution on neurologic health, disease, and practice: a scoping review S Louis, AK Carlson, A Suresh, J Rim, MA Mays, D Ontaneda, A Dhawan Neurology 100 (10), 474-483, 2023 | 74 | 2023 |
| Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, ME Cudkowicz, T Gleason, A Goodman, EC Klawiter, ... Contemporary clinical trials 50, 166-177, 2016 | 74 | 2016 |
| Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up CM Hersh, TE Love, A Bandyopadhyay, S Cohn, C Hara-Cleaver, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 3 (3 …, 2017 | 73 | 2017 |
| Imaging outcome measures of neuroprotection and repair in MS: a consensus statement from NAIMS J Oh, D Ontaneda, C Azevedo, EC Klawiter, M Absinta, DL Arnold, ... Neurology 92 (11), 519-533, 2019 | 72 | 2019 |
| Imaging as an outcome measure in multiple sclerosis D Ontaneda, RJ Fox Neurotherapeutics 14 (1), 24-34, 2017 | 72 | 2017 |
Jeffrey A CohenCleveland ClinicDirección de correo verificada de ccf.org
